Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06652555 | The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study | not yet recruiting | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER |
| 0 |
| Oct 22, 2024 |
| clinicaltrials |
| NCT06645743 | Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma | not yet recruiting | — | 1,100 | The Third Affiliated Hospital of Kunming Medical College.OTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646770 | SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)(SELTIC) | not yet recruiting | N/A | 400 | Istanbul University - CerrahpasaOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06643910 | A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer | not yet recruiting | N/A | 12 | BioSyngen Pte LtdINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644313 | Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 31 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06618391 | Local Injection and Systemic Therapy in the Treatment of NSCLC. | not yet recruiting | Phase 2 | 84 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial | not yet recruiting | Phase 2 | 296 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614231 | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06607926 | Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC | not yet recruiting | N/A | 40 | Xuanwu Hospital, BeijingOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06586801 | The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China | not yet recruiting | — | 800 | Shanghai East HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06591910 | Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer | not yet recruiting | — | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06594874 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | not yet recruiting | Phase 1 | 350 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602661 | Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy | not yet recruiting | Phase 1 | 65 | Surrey Thoracic Surgery GroupOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06604351 | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction(Example) | not yet recruiting | Phase 2 | 39 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585059 | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers | not yet recruiting | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06580665 | Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer | not yet recruiting | N/A | 134 | Shanghai Chest HospitalOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06557096 | CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC | not yet recruiting | Early Phase 1 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06502249 | Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) | not yet recruiting | — | 60 | Ain Shams UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06475755 | Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC | not yet recruiting | Phase 2 | 178 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06454890 | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 12, 2024 | clinicaltrials |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 11, 2024 | clinicaltrials |
| NCT06434740 | A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC | not yet recruiting | Phase 2 | 37 | Sir Run Run Shaw HospitalOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06436144 | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 93 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | May 30, 2024 | clinicaltrials |
| NCT06414915 | Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 29 | National Cancer Center, ChinaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT05859217 | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)(Cabatezo-1) | not yet recruiting | Phase 2 | 40 | Jun Zhang, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06380348 | JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations | not yet recruiting | Phase 3 | 398 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Apr 23, 2024 | clinicaltrials |
| NCT06336954 | Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Mar 29, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06329648 | Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer(DECIDE) | not yet recruiting | — | 20,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06299371 | Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | not yet recruiting | Phase 2 | 36 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06282536 | Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | not yet recruiting | Phase 2 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06254599 | A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | not yet recruiting | Phase 3 | 255 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06221462 | Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer(PRIORITY) | not yet recruiting | Phase 2 | 30 | Ningbo No.2 HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT06218940 | HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC | not yet recruiting | Phase 1 | 40 | Newsoara Biopharma Co., Ltd.INDUSTRY | 0 | Jan 23, 2024 | clinicaltrials |
| NCT06198907 | Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)(JACKPOT33) | not yet recruiting | Phase 2 | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06185400 | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | not yet recruiting | Phase 2 | 108 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2023 | clinicaltrials |
| NCT06182761 | A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer(WUKONG-9) | not yet recruiting | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06142617 | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | not yet recruiting | Phase 2 | 37 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06127329 | Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC | not yet recruiting | N/A | 70 | Gang WuOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06117644 | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | not yet recruiting | — | 30 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Nov 7, 2023 | clinicaltrials |
| NCT05988697 | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | not yet recruiting | — | 36 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06067776 | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | not yet recruiting | Phase 1 | 36 | Jonathan RiessOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2024source: clinicaltrials